---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010978"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:05:37.926155+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma reports FY2022 revenue $67.8M, cash runway into H2 2024; plans luvelta Phase 2/3 in Q2 2023

## Summary
- Cash and investments of $302.3M plus Vaxcyte stock valued at $32.0M provide cash runway into H2 2024.
- Revenue for FY2022 was $67.8M, up from $61.9M in FY2021, driven by collaboration payments.
- Total operating expenses were $196.7M, up from $160.4M, with R&D at $137.2M and G&A at $59.5M.
- Plans to initiate Phase 2/3 registration-directed study of luvelta in platinum-resistant ovarian cancer in Q2 2023.
- Dr. Anne Borgman appointed Chief Medical Officer in February 2023.

## SEC filing metadata
- accession: 0000950170-23-010978
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/stro-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010978
- JSON: https://secwatch.observer/filing/0000950170-23-010978.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010978.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported financial results for the full year 2022.
  - Period: the full year 2022
  - Result: reported results
  source text: On March 30, 2023, Sutro Biopharma, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017023010978/0000950170-23-010978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.